title: NX-1207: a novel investigational drug for the treatment of benign prostatic hyperplasia.
abstract: BACKGROUND
  Lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) is a common affliction among older men that can have significant impact on health-related quality of life. BPH is a progressive condition that can lead to complications including acute urinary retention (AUR) and to surgical intervention. There is an ongoing need for new, safe and effective treatments for BPH. Currently available therapies have significant safety and efficacy limitations. NX-1207 is a promising first-in-class drug currently in Phase III trials for the treatment of BPH.
  
  
  METHODS
  This review provides an overview of BPH and currently approved medical treatments and drugs as described in the literature and treatment practice guidelines in the past 10 years, an outline of the results of the Phase II trials of NX-1207 and an expert opinion on the role NX-1207 may play in the treatment of men with clinical BPH.
  
  
  RESULTS
  This review aims to introduce readers to NX-1207, a new treatment for BPH that is administered in an office-based procedure by transrectal intraprostatic injection under ultrasound guidance. NX-1207 has selective pro-apoptotic properties, which induces focal cell loss in prostate leading to prostate volume reduction with both short- and long-term symptomatic improvement.
  
  
  CONCLUSIONS
  In four US clinical trials to date, NX-1207 has shown evidence of symptomatic improvement substantially better than currently approved BPH medications with no significant safety issues. Larger Phase III trials are ongoing to further confirm the efficacy, safety and tolerability for this minimally invasive, anesthetic free, clinic-based treatment for BPH.
authors.affiliation: Carolina Urologic Research Center, 823 82nd Parkway, Myrtle Beach, SC 29572, USA. nshore@grandstrandurology.com
authors.forename: Neal
authors.initials: N
authors.lastname: Shore
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D042944:Cholestenone 5 alpha-Reductase / Q000037:antagonists & inhibitors; D004341:Drug Evaluation; D015507:Drugs, Investigational / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008872:Microwaves / Q000627:therapeutic use; D011467:Prostate / Q000187:drug effects / Q000601:surgery; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000601:surgery / Q000628:therapy; D016032:Randomized Controlled Trials as Topic
chemical_list: D000317:Adrenergic alpha-Antagonists; D015507:Drugs, Investigational; D042944:Cholestenone 5 alpha-Reductase